AI Insights

Global Artificial Intelligence in Oncology Market Size to Hit

Published

2 months ago

July 14, 2025

Artificial intelligence (AI) [https://www.coherentmarketinsights.com/industry-reports/global-artificial-intelligence-in-oncology-market] is playing an increasingly important role in oncology. There are various types of AI products that are helping in cancer screening, diagnosis, treatment, and drug development. One of the major products is an AI-assisted cancer screening tool. These tools use deep learning algorithms that have been trained on huge databases of medical images.

Request Sample Report: [https://www.coherentmarketinsights.com/insight/request-sample/6509]

Global Artificial Intelligence in Oncology Market Key Takeaways

According to Coherent Market Insights (CMI), the global artificial intelligence in oncology market size is expected to grow more than 7.6X, from USD 2,145.1 Mn in 2025 to USD 16,382 Mn by 2032, exhibiting a robust CAGR of 33.7%.

Based on component, software/platform segment is anticipated to account for a prominent market share of 64.2% in 2025.

North America is expected to retain its dominance, accounting for more than one-third of the global artificial intelligence in oncology market share in 2025.

Europe is projected to remain the second-leading market for AI-powered oncology companies.

As per Coherent Market Insights’ new global artificial intelligence in oncology market analysis, Asia Pacific is poised to witness fastest growth throughout the assessment period.

Increasing Cancer Prevalence Spurring Market Growth

Coherent Market Insights’ latest global artificial intelligence in oncology market research report highlights key factors driving market growth. One such prominent growth factor is the rising incidence of cancer.

The IARC’s Global Cancer Observatory projects that annual new cancer cases will surpass 35 million by 2050. This sharp rise in cancer incidence is anticipated to drive demand for artificial intelligence in oncology.

Artificial intelligence is revolutionizing oncology by enhancing cancer detection, treatment planning, and drug discovery. Therefore, growing cancer burden is poised to play a crucial role in driving adoption of AI-based oncology solutions over the forecast period.

High Implementation Costs and Data Privacy Concerns Restraining Market Growth

The global artificial intelligence in oncology market outlook indicates strong future growth. However, high implementation costs and data security concerns are limiting market growth to some extent.

Integrating AI technologies into oncology workflows requires significant investment in hardware and software. This deters small and mid-sized healthcare companies from opting for these technologies, thereby reducing global artificial intelligence in oncology market demand.

AI systems require access to large amounts of patient data, raising concerns about cybersecurity risks as well as potential misuse. This may also negatively impact the global artificial intelligence in oncology market growth during the projection period.

Get Instant Access! Purchase Research Report and Receive a 25% Discount: [https://www.coherentmarketinsights.com/insight/buy-now/6509]

Technological Advancements in AI Creating New Growth Prospects for the Market

Ongoing innovations in deep learning, computer vision, and natural language processing (NLP) are significantly enhancing AI applications in image analysis, drug discovery, and prognosis prediction. Such breakthroughs are expected to unlock new revenue-generation streams for industry players.

Advanced AI technologies are being increasingly integrated with imaging modalities like MRI and PET scans. This integration enables automated detection of anomalies, enhances diagnostic accuracy, and reduces human error.

Emerging Global Artificial Intelligence in Oncology Market Trends

Rising demand for precision medicine is a key growth-shaping trend in the market. Precision oncology requires analyzing large datasets, including genomics and biomarkers. This is where AI steps in, processing huge data and enabling creation of individualized therapies.

Expanding use of artificial intelligence in radiology and pathology is expected to boost the market. AI technologies are being increasingly used for tumor detection, segmentation, and classification through radiological and histopathological images. This is due to their ability to improve speed and consistency as well as reduce diagnostic errors.

Increasing adoption of AI in drug discovery and development is positively impacting the global artificial intelligence in oncology market value. This advanced technology is revolutionizing drug discovery by rapidly analyzing large datasets to identify potential drug candidates as well as predict their efficacy and toxicity.

Growing adoption of cloud-based AI solutions is significantly contributing to the expansion of the global artificial intelligence in oncology market. These solutions are increasingly favored for their cost-efficiency, scalability, and ability to provide seamless remote access to data and tools.

Request Customization: [https://www.coherentmarketinsights.com/insight/request-customization/6509]

Analyst’s View

” The global artificial intelligence in oncology market is set for rapid expansion, owing to growing prevalence of cancer, rising adoption of precision medicine, and technological advancements in AI technologies,” said senior analyst Komal Dighe.

Current Events and Their Impact on the Global Artificial Intelligence in Oncology Market

Event

Description and Impact

FDA Clears First GenAI-Powered Diagnostic Tool for Breast Cancer Detection (2025)

* Description: The U.S. FDA approved a GenAI-based diagnostic platform by PathIntel, capable of identifying breast cancer subtypes with high accuracy using real-world data.

* Impact: Such approvals signal growing regulatory acceptance of generative AI in oncology.

Tempus Collaborated with Boehringer to Accelerate AI Usage in Oncology

* Description: In May 2025, Tempus entered a multi-year strategic collaboration with Boehringer Ingelheim to apply its AI-driven oncology insights toward cancerfocused therapeutic discovery and biomarker development

* Impact: This will likely boost growth of the AI in oncology market.

Japan’s MHLW Updates Reimbursement Guidelines for AI Diagnostics

* Description: Japanese Ministry of Health, Labour and Welfare (MHLW) has approved reimbursement for certain AI-enhanced imaging diagnostics

* Impact: Such initiatives will increase commercial viability and adoption of AI oncology tools in Asia-Pacific, spurring more localized R&D and product launches.

Competitor Insights

Key companies listed in the global artificial intelligence in oncology market report:

– IBM Corporation

– Intel Corporation

– Azra AI

– NVIDIA Corporation

– Siemens Healthineers AG

– GE HealthCare

– Digital Diagnostics Inc.

– ConcertAI

– PathAI

– Median Technologies

– Microsoft

– Babylon

– Zebra Medical Vision

Key Developments

In June 2025, Viz.ai launched a new strategic alliance with Novartis to accelerate timely diagnosis and deliver AI-powered precision care for cancer patients. Through this collaboration, Viz.ai will focus on developing AI-powered workflows for breast and prostate cancer.

In November 2024, PathAI unveiled PathExplore Fibrosis. This new AI-powered tool is designed to revolutionize collagen, fibrosis, and fiber quantification directly from whole-slide images.

In January 2024, PathAI launched six additional oncology indications for PathExplore, expanding the AI-driven pathology panel to cover ovarian, bladder, liver, small cell lung, lymphoma, and head & neck cancers.

Global Artificial Intelligence in Oncology Market Segmentation:

By Component

Software/Platform

Hardware

Services

By Cancer Type

Breast Cancer

Lung Cancer

Prostate Cancer

Colorectal Cancer

Brain Tumor

Others

By Treatment Type

Chemotherapy

Radiotherapy

Immunotherapy

Others

By End User:

Hospitals & Clinics

Diagnostic Centers

Biopharmaceutical Companies

Others

By Region

North America

Latin America

Europe

Asia Pacific

Middle East

Africa About Us:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

Media Contact
Company Name: Coherent Market Insights
Contact Person: Mr. Shah
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=global-artificial-intelligence-in-oncology-market-size-to-hit-usd-21451-million-by-2025-grow-at-a-cagr-of-337-coherent-market-insights]
Phone: + 12524771362
Address:533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States
Country: United States
Website: https://www.coherentmarketinsights.com/industry-reports/global-artificial-intelligence-in-oncology-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com

This release was published on openPR.

Source link

Up Next

I asked ChatGPT to make an image describing my life, but first I had to correct some errors

Don't Miss

How AI Is Ushering in a New Era for the Healthcare System

The Editors

Click to comment

AI Insights

Artificial intelligence can predict risk of heart attack – mydailyrecord.com

Published

32 minutes ago

September 11, 2025

The Editors

Artificial intelligence can predict risk of heart attack mydailyrecord.com

Source link

AI Insights

China’s Open-Source Models Are Testing US AI Dominance

Published

58 minutes ago

September 11, 2025

The Editors

While the AI boom seemingly began in Silicon Valley with OpenAI’s ChatGPT three years ago, 2025 has been proof that China is highly competitive in the artificial intelligence field — if not the frontrunner. The Eastern superpower is building its own open-source AI programs that have demonstrated high performance as they put ubiquity and effectiveness over profitability (while still managing to make quite a bit of money), the Wall Street Journal reports.

DeepSeek is probably the most well-known Chinese AI entity in the U.S., whose R1 reasoning model became popular at the start of the year. Being open-source, as opposed to proprietary, means these programs are free and their source code can be downloaded, used and tinkered with by anyone. Qwen, Moonshot, Z.ai and MiniMax are other such programs.

This is in contrast to U.S. offerings like ChatGPT, which, though free to use (up to a certain level of compute), are not made available to be modified or extracted by users. (OpenAI did debut its first open-source model, GPT-OSS, last month.)

American companies like OpenAI are racing to catch up — monopolies and industry-standard technologies are often the ones that are the most accessible and customizable. The Trump administration wagered that open-source models “could become global standards in some areas of business and in academic research” in July.

Want to join the conversation on how the security of information and data is impacting our global power struggle with China? Attend the 2025 Intel Summit on Oct. 2, from Potomac Officers Club. This GovCon-focused event will include a must-attend panel discussion called “Guarding Innovation: Safeguarding Research and IP in the Era of Strategic Competition With China.” Register today!

China has already declared an economic war on the West using espionage at the forefront of its campaign. —David Shedd

China’s Tech Progress Has Big Implications

The Intel Summit panel will feature, among other distinguished guests, David Shedd, a highly experienced intel community official who was acting director of the Defense Intelligence Agency (after serving as its deputy director for four years) and deputy director of national intelligence for policy, plans and procedures.

Shedd spoke to GovCon Wire in an exclusive interview about China-U.S. competition ahead of his appearance on the panel. He said that China’s progress in areas like AI should not be taken lightly and could portend greater problems and tension in the future.

“Sensitive IP or technological breakthroughs in things like AI, stealth fighter jets, or chemical formulas lost to an adversary do not happen in a vacuum. They lead, instead, to the very direct and very serious loss of the relative capabilities that define and underpin the balance and symbiosis of relationships within the international system,” Shedd commented.

Open-source models are attractive to organizations, WSJ said, because they can customize the programs and use them internally and protect sensitive data. In their Intel Summit panel session, Shedd and his counterparts will explore how the U.S. might embrace open-source more firmly as a way to stay agile in the realm of research and IP protection.

Who Is Stronger, America or China?

Shedd, along with co-author Andrew Badger, is publishing a book on December 2 entitled “The Great Heist: China’s Epic Campaign to Steal America’s Secrets.” Published through HarperCollins, the volume will focus on the campaign of intellectual property theft the Chinese government is waging against the U.S.

Shedd elaborated for us:

“The PRC/CCP’s unrelenting pursuit of stolen information from the West and the U.S. in particular has propelled China’s economic and military might to heights previously unimaginable. Yet we collectively continue to underestimate the scale of this threat. It’s time for the world to fully comprehend the depth and breadth of China’s predatory behavior.

Our national security depends on how we respond—and whether we finally wake up to the reality that China has already declared an economic war on the West using espionage at the forefront of its campaign. It already has a decades-long head start.”

Don’t miss former DIA Acting Director David Shedd, as well as current IC leaders like Deputy Director of National Intelligence Aaron Lukas and CIA’s AI office Deputy Director Israel Soong at the 2025 Intel Summit on Oct. 2! Save your spot before it’s too late.

https://www.youtube.com/watch?v=videoseries

Source link

AI Insights

Move Over Palantir. This Artificial Intelligence (AI) Stock Just Took Over as the S&P 500’s Best Performer in 2025.

Published

1 hour ago

September 11, 2025

The Editors

This AI-driven megatrend has sent this stock and its closest competitor rocketing higher in 2025.

Many artificial intelligence (AI) stocks have zoomed higher over the last three years, following the introduction of OpenAI’s ChatGPT. One of the biggest winners, by far, has been Palantir Technologies (PLTR 2.70%). The enterprise software company integrated generative AI into its software in 2023, and it’s seen sales and profits soar ever since. The stock is up a cumulative 2,500% since the start of 2023, including a 120.7% rise in 2025 alone, as of this writing.

Up until last week, that was good enough to make it the best performer in the S&P 500 at the moment. But another stock overtook the market darling’s year-to-date performance at the start of September, boosted by the voracious demand for artificial intelligence. Say hello to the new best-performing stock in the S&P 500.

Image source: Getty Images.

Essential infrastructure for AI data centers

Big tech companies are spending hundreds of billions of dollars on building out data centers and outfitting them with servers. Chipmakers like Nvidia have benefited greatly as demand for graphics processing units (GPUs) and custom AI accelerators continues to climb. But there’s another important component to building out data centers: Storage.

AI training is extremely data-intensive. While some of that data needs to be readily accessible quickly, a lot of it can be held in what’s called “nearline” storage. Nearline storage might take a few seconds to access, but it’s a cheap and effective way to maintain the huge amounts of data needed for large language models.

Hard drive maker Seagate Technology (STX 0.76%) has seen demand for nearline storage explode, helping push its stock to a 121.4% gain so far this year, as of this writing. That’s better than every other stock in the S&P 500, including Palantir.

The company shipped 137 exabytes of capacity to data center customers last quarter, up 14% sequentially and 52% year over year. The financial results are just as impressive. Revenue grew 39% in fiscal 2025. Gross profit margin expanded to 35.2% from 23.4% last year. Fourth-quarter gross margin was even more impressive at 37.4%, as the market remains supply-constrained.

Seagate is one of two major suppliers of hard drives. Western Digital (WDC 0.51%) remains its biggest rival, maintaining a nearly equal share of the market. Unsurprisingly, Western Digital is also a top-performing stock this year, as it benefits from the exact same mega trend as Seagate. While both have made strides in increasing storage capacity per unit, there’s still a limit to how much each can produce. Thus, they’ve both seen strong gross margin expansion.

Tech companies are planning to keep spending on new data centers and the necessary increased storage capacity that comes along with them. Seagate’s management expects data center storage demand to climb from $13 billion in 2024 to $23 billion by 2028. Western Digital shared a similar outlook at its investor day in February. As a result, the current cycle of growth could extend for years to come.

Is it worth the price?

Hard drives are kind of a commodity for data centers. A buyer could use any supplier, and the hard drives will fit into the same exact spot in their data center as any other hard drive would. The only major difference is how much storage capacity each drive has, which makes price per terabyte (TB) the biggest deciding factor for a buyer.

As a result, competition between Seagate and Western Digital has typically kept pricing low and pushed new technology forward relatively quickly. Margin expansion only really happens when there’s a huge demand cycle like we’re currently seeing. When the cycle ends, and it will, both companies will see deterioration in their margins until the next uptick in demand.

Seagate seems to have developed a slight technology lead. Its heat-assisted magnetic recording (HAMR) process is on track to be able to scale production of 40TB hard drives by the second half of fiscal 2026 (early calendar 2026). Western Digital isn’t on track to start mass production of 40TB hard drives — it’s about six months behind. That could open the door for Seagate to take some market share over the next few years and grow slightly faster than its chief rival.

At a forward price-to-earnings (P/E) ratio of 18.5, investors may think Seagate is an absolute bargain compared to most AI stocks. When you compare it with Palantir’s eye-popping 245 times earnings multiple, it seems extremely cheap. But it’s important to put that in context.

While Seagate is growing earnings extremely quickly right now, it’s still in a cyclical industry. Cyclical stocks tend to trade at much more attractive earnings multiples amid upcycles in demand. That’s because they could see a massive drop in earnings power if demand dries up, or even if supply growth starts to outpace demand.

For a point of reference, Western Digital trades for a forward P/E ratio close to 14. While Seagate may deserve a slight premium to Western Digital, both are trading at a premium to their historic pricing over the past year after their recent run to put them at the top of the S&P 500’s best-performers list. At this point, it might be worth waiting for a better price on both stocks before buying into the latest big winner from artificial intelligence spending.

Adam Levy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia and Palantir Technologies. The Motley Fool has a disclosure policy.

Source link